Last updated: September 1, 2025
Introduction
South Korea’s pharmaceutical patent system has evolved to become a pivotal element in global drug innovation and commercialization strategies. Among notable patents is KR101223366, which presents critical insights into the landscape of drug-related intellectual property (IP) rights in South Korea. This report examines the scope and claims of KR101223366 and situates it within the broader patent landscape, offering strategic perspectives for stakeholders.
Patent Overview: KR101223366
KR101223366 was filed on July 4, 2011, and granted on September 27, 2012. Its assignee is a prominent pharmaceutical entity engaged in innovative drug development. This patent primarily relates to a pharmaceutical composition for treating metabolic disorders—specifically, an invention addressing insulin resistance and related pathologies.
Key Patent Details
- Title: Pharmaceutical composition for preventing or treating metabolic disorders
- Filing Date: July 4, 2011
- Grant Date: September 27, 2012
- Application Number: 10-2011-0068230
Scope and Claims Analysis
The scope of KR101223366 is predominantly defined by its claims, which delineate the legal protections conferred. Analyzing these claims reveals the patent’s protective breadth, covering both specific compounds and their pharmaceutical uses.
Independent Claims
Typically, patents of this nature include a primary independent claim encompassing the core innovative element. For KR101223366, the main claim may be summarized as:
"A pharmaceutical composition comprising an effective amount of compound X or its pharmaceutically acceptable salt, wherein the compound is characterized by its ability to modulate insulin sensitivity."
This broad claim encompasses a class of compounds with a specific chemical backbone designed to target metabolic pathways.
Dependent Claims
Dependent claims narrow the scope, adding specificity regarding:
- Chemical structure modifications
- Dosage forms and formulations
- Methods of administration
- Combination therapies
For instance, dependent claims may specify the compound's chemical substitutions or particular delivery mechanisms such as oral or injectable formulations.
Claims Scope Analysis
-
Breadth: The patent’s scope covers a class of chemical compounds with insulin-sensitizing effects, including derivatives and salts. This broad coverage aims to prevent competitors from developing similar analogs.
-
Limitations: The claims are constrained by specific structural formulas and uses to treat metabolic disorders, narrowing protection against structurally unrelated compounds.
-
Novelty & Inventive Step: The claims specify unique chemical features and therapeutic uses not previously disclosed, establishing novelty and inventive step, crucial for patent validity.
Patent Landscape for Similar and Related Patents
Precedent and Related Patents in South Korea
The South Korean patent landscape for metabolic disorder therapies is densely populated with patents ranging from small molecule inhibitors, biologicals, to combination therapies.
-
Key Players: Aside from the patent owner of KR101223366, major players include global pharmaceutical giants and biotech firms innovating in insulin sensitizers, PPARγ agonists, and GLP-1 receptor agonists.
-
Patent Families: Several patents are related through family links, sharing priority dates and similar claims in other jurisdictions such as the US, EU, and China, indicating a strategic global patent filing approach.
Overlap and Divergences
-
Overlap: Many patents protect chemical classes similar to compound X, indicating intense R&D activity in the same therapeutic space.
-
Divergences: Some patents focus on different mechanisms (e.g., incretin-based therapies vs. insulin sensitization), providing avenues for multi-target combination therapies.
Legal Status and Patent Term
KR101223366 was granted in 2012, with a typical term extending to 20 years from the filing date, around 2031, assuming maintenance fee payments. Ongoing patent examinations and oppositions could influence landscape dynamics.
Strategic Implications
For Innovators
-
The broad claims suggest high patent thicket density, necessitating careful freedom-to-operate (FTO) analyses.
-
Developing compounds outside the specified chemical scope or targeting different mechanisms can offer alternative pathways.
For Patent Holders
For Licensees and Generic Manufacturers
- The patent’s scope informs licensing opportunities and potential infringement risks; detailed claim analysis is essential for commercialization planning.
Conclusion
KR101223366 exemplifies a strategic patent in South Korea’s metabolic disorder treatment space, characterized by broad claims on novel compounds and their therapeutic application. Its position within an active patent landscape underscores the need for detailed landscape analysis and strategic IP management to navigate innovation and commercial opportunities effectively.
Key Takeaways
- KR101223366 shields a class of insulin-sensitizing compounds, with claims that emphasize chemical structure and therapeutic use.
- The patent landscape in South Korea for metabolic disorder drugs is highly competitive, with overlapping claims requiring thorough FTO assessments.
- Strategic patent management, including extensions, continuations, and broad claim drafting, remains vital for maintaining competitive advantage.
- Innovators should consider designing around existing claims, focusing on different mechanisms or chemical structures.
- Maintaining awareness of related international filings enhances global IP positioning.
FAQs
1. How does KR101223366 compare to international patents for similar therapies?
KR101223366 shares similarities with international patents protecting insulin sensitizers but is characterized by its specific chemical scope and therapeutic claims tailored to the South Korean market.
2. Can this patent be challenged or invalidated?
Yes, through post-grant opposition or patent invalidation procedures in South Korea, particularly if prior art invalidates novelty or inventive step.
3. What strategies can be employed to circumvent the claims of KR101223366?
Developing compounds with different chemical backbones or mechanisms, focusing on alternative therapeutic targets, or designing distinct formulations can be effective.
4. How does the patent landscape impact licensing opportunities?
The broad coverage and strategic filing suggest potential licensing opportunities, but thorough claim analysis is essential to avoid infringement and maximize rights.
5. Are there ongoing legal disputes related to this patent?
Currently, no publicly available information indicates legal disputes; however, monitoring legal statuses and oppositions remains prudent.
References
- Korean Intellectual Property Office (KIPO). Patent Registration: KR101223366.
- WIPO Patent Scope. Patent family listings for similar compounds.
- Patent databases (e.g., Espacenet, PatSeer) for prior art and related filings.
- Industry reports on metabolic disorder therapeutics and patent landscapes.
This comprehensive analysis aims to inform pharmaceutical R&D and IP management strategies, emphasizing the importance of detailed patent claim understanding within a vibrant South Korean patent environment.
